ProMIS NeurosciencesPMN
Recorded

ProMIS Neurosciences 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Eddie HickmanAnalyst

Hickman. I am one of the biotech analysts here at Guggenheim, and I am joined by my colleague, Yatin Suneja, and the CEO of ProMIS Neurosciences, Neil Warma. Neil, thank you so much for being here and joining us. Maybe before we start, for anyone who is not familiar with ProMIS, just give us a short background on the company and some news from the year and some upcoming catalysts that you are looking forward to.

Neil WarmaCEO

Yeah, of course, Eddie. Thanks again for the invitation to the conference, Yatin, you as well. Excited to be here with Larry Altstiel, our Chief Medical Officer, is in the audience with us as well. Yeah, been a fascinating year for ProMIS. Our focus has been very much on executing and enrolling and dosing patients in our phase I-B clinical study in Alzheimer's disease. ProMIS Neurosciences is a company that is technology platform is based around misfolded proteins, so the ability to design antibodies that are highly selective to a specific form, a misfolded form of a protein for a specific disease. So we are developing a next-generation anti-amyloid monoclonal antibody for the treatment of Alzheimer's disease. Again, our trial is fully enrolled. We are now completing dosing and finishing off patients in this study. We have enrolled 144 subjects, and we are expecting top-line data coming soon in the next few months.

Neil WarmaCEO

We have guided towards top-line data Q1 of 2027.

Eddie HickmanAnalyst

Great. No, thanks for that. Before we dig into the data you have shown already and sort of what we should expect- Sure in 1Q, maybe can we step back and talk a little bit about your hypothesis, which is different from what some of the approved therapies in this space have done, and how you think targeting the toxic oligomers is sort of different from a plaque-targeting antibody?

Neil WarmaCEO

Yeah, sure. I mean, just to be clear, it's consistent with a few players out there that have tried to design antibodies to go after the toxic oligomer species. We're certainly not alone in recognizing that the oligomer species of amyloid beta protein appears to be the most toxic form of amyloid beta protein. When you look at lecanemab that's on the market, their aspirations and their goal was to design an antibody that selectively bound to the upstream toxic oligomers. We are, again, we're kind of part of this field who truly believes that the oligomer hypothesis is front and center in driving cognitive decline in Alzheimer's disease. I think the differentiation from our perspective is being able to design an antibody that truly is selective to that toxic species.

Neil WarmaCEO

While others have tried, I think almost, well, every other drug candidate that's tried to be selective to the oligomers also binds other species and other forms of amyloid beta. We see with the other drugs on the market and in development, they also bind to plaque, for example, and we now know that plaque is not really associated with cognitive decline in Alzheimer's patients. There's drugs that completely clear plaque, and patients continue to decline. We now have shifted the thinking to these toxic oligomers, but again, the challenge for other drugs, other companies, is to design a drug candidate or an antibody that can avoid the other forms of amyloid beta and just hit the toxic species.

Neil WarmaCEO

That's where our platform, our ability to predict how proteins are going to misfold, and therefore design antibodies that are exclusively selective to a given target, and in our case, these toxic oligomers, we're able to differentiate ourself. Again, a similar mechanism to what people are thinking, trying to get to the oligomers, but we're truly differentiated, and we believe we have the kind of only antibody that's in development or on the market that does selectively target these oligomers.

Eddie HickmanAnalyst

Yeah. Maybe quickly just talk about the data you have shown so far pre-clinically and now maybe even early clinical data that shows that you are targeting that species specifically.

Neil WarmaCEO

Yeah, sure. I mean, it is important to us that, I mean, we have been doing this for a number of years now, and every step of the way, and again, our hypothesis, back in the days when it was not even that popular to talk about toxic oligomers, but we stuck to that method because we truly believed that to be true. And every piece of data that we have produced since then has supported our hypothesis, and that is really important as opposed to changing our story as the data come out. For us pre-clinically, and we tested this in many different ways to show that, are we truly selective to the oligomers? We did a monomer competition assay which showed that we did not bind monomers.

Neil WarmaCEO

We did side-by-side analyses, multiple different assays testing PMN310, the ProMIS candidate, alongside donanemab, aducanumab, lecanemab, ACU193, which of these proteins does or does not bind to plaque? And in every single case, PMN310 was the only antibody that did not bind plaque. All the others bound plaque to some degree, and they have shown that in clinical data readout as well. So we took that knowledge from the pre-clinical set of studies, and then marched ahead into the clinic, confident that we had something truly differentiated. And then we did a phase I-A clinical trial in healthy volunteers, and that showed that the antibody was safe and well-tolerated. It also importantly showed that the antibody crossed the blood-brain barrier in sufficient quantities to more than fully engage the oligomer target. So the 1A was successful, supported our hypothesis.

Neil WarmaCEO

And then most recently, Eddie, as you know, we kind of embarked on, and we can maybe touch on this in a minute, but we embarked on a phase I-B clinical study in MCI patients, so mild cognitive impairment due to Alzheimer's, so early Alzheimer's patients. And we built an interim analysis into that study, and we announced the results of this blinded interim analysis. When patients had been treated for six months, we looked at safety and biomarker movement. Again, maybe we come back to what those data showed in just a minute, but on the hypothesis that, are we selective to oligomers and avoiding plaque, like the original hypothesis had dictated, the interim analysis showed that kind of exquisitely, that the level of ARIA that we saw with the interim analysis were zero cases of ARIA-E and just mild background, kind of placebo-like rates of mild asymptomatic ARIA-H.

Neil WarmaCEO

So we, again, consistent in that hypothesis of avoiding plaque and eliminating much of the ARIA liability, we've been consistent all the way through our clinical and preclinical development.

Yatin SunejaAnalyst

Thank you, Neil. I would agree. I think the data that you have shown from just an interim analysis on a blinded basis look very different and unique than anything out there, at least on the ARIA front. But I have to ask you this. We recently saw, and I'm sure you also saw, the ALTITUDE-AD result. What was your reaction? Should there be any read-through to PMN310?

Neil WarmaCEO

Yeah, it was an interesting result, and you feel for the patients and the caregivers first and foremost. But again, and I don't think the results were overly surprising. The reaction was surprising. The results, the data that we saw, and it was limited data, but were not that surprising. Again, if you look at that product, sabirnetug from ACU193, as it's come through development, despite claims otherwise, I mean, that's an antibody that is not selective to the oligomer species. It binds multiple different forms of amyloid beta, including plaque. So the fact that it came with double-digit rates of ARIA-E and plaque clearance was not a surprise, because again, they had showed that in the earlier clinical studies, so that was kind of consistent with previous data. I think the messaging might have been a little bit disconnected from the data.

Neil WarmaCEO

It wasn't a surprise to see ARIA-E levels and minimal efficacy. So I think that drug probably does bind oligomers to some degree, but we're not sure exactly what it does bind, but we know it's multiple different species of amyloid beta. So not overly surprising to see that result. And certainly, we don't believe speaks to the oligomer hypothesis, because as I said, we've been touting this, as other companies and as they did as well, that the oligomer species is the driver of cognitive decline. But what they fail to have in hand is an antibody that selectively targets oligomers.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day